Ingenza has undergone significant transformation and growth since its inception in 2003, which would not have been possible without a talented and multifaceted team lending their collective expertise to the development and commercialisation of biobased products. New positions and responsibilities…
Ingenza is excited to welcome Dr Mark Chadwick to the team as Strategic Business Advisor. Mark will bring extensive industry expertise to his new position at Ingenza, acquired over 30 years from a variety of roles within small growth companies,…
Edinburgh-based Ingenza, a pioneer in engineering biology, is pleased to announce the appointment of Dr Ian Shott CBE, FREng to the board as Executive Chairman. Ian joins Ingenza with over 35 years of experience in the global life science and biotechnology…
Industrial biotech specialist Ingenza is delighted to announce that it is collaborating with clinical-stage biopharmaceutical company Amplifica Holdings Group, Inc. to develop an innovative treatment to address androgenic alopecia. Amplifica has partnered with Ingenza to advance the development of its…
Dr Connor Bowen is a Senior Scientist working within the molecular biology team at Ingenza. He received his undergraduate degree from the University of Dundee, and followed it up with a PhD and post doc at the same institution, studying Serratia…
Ingenza has delivered a new, proprietary biomanufacturing process for human recombinant factor VIII (rhFVIII) to Scottish biotechnology company ProFactor Pharma Ltd (PFP), which will considerably increase global access to low-cost treatment for haemophilia A. The novel bioprocess underpins PFP’s recent…
Maintaining quality in all aspects of a business is a vital part of any company’s operations, and the cornerstone of its success. Quality management enables effective planning, control and continuous improvement, all with the aim of providing customers with products…
Jul 5, 2022 – The Coalition for Epidemic Preparedness Innovations (CEPI) has partnered with a consortium of research and technological institutions to develop a novel vaccine to provide protection against COVID-19 caused by current and future SARS-CoV-2 variants, as well as…
Biotechnology company Ingenza is delighted to announce that its recent partnership with Johnson Matthey has been selected to receive vital funding of £441,632.88 from the Department of Business, Energy and Industrial Strategy as part of the £1 billion fund from the…
I started with Ingenza in 2010 as a research assistant in the molecular biology department, upon completing a BSc in infection biology at the University of Glasgow. After two years in that position, I moved across to a role in…